Nifty slips below 11,000

Image
Capital Market
Last Updated : Aug 21 2019 | 9:50 AM IST

Negative Asian stocks took their toll on domestic stocks in early trade. At 9:21 IST, the barometer index, the S&P BSE Sensex, was down 56.53 points or 0.15% at 37,271.48. The Nifty 50 index was down 17.80 points or 0.16% at 10,999.20. The Nifty fell below the psychological 11,000 level in early trade.

The S&P BSE Mid-Cap index was down 0.27%. The S&P BSE Small-Cap index was down 0.19%. Both these indices underperformed the Sensex.

The market breadth, indicating the overall health of the market, was negative. On the BSE, 386 shares rose and 539 shares fell. A total of 45 shares were unchanged.

Overseas, Asian shares were trading lower on Wednesday as fresh worries about a global recession led investors to dump risky assets, with US President Donald Trump showing no signs of backing down in his trade war with China.

Financial shares led US stocks lower on Tuesday to end a three-day rally as investors awaited comments from Federal Reserve Chair Jerome Powell at the end of the week.

Back home, Dr Reddy's Laboratories lost 1.85%. The company said that the audit of Formulations Manufacturing plant (Vizag SEZ Plant 1) at Duvvada, Visakhapatnam by the US FDA, has been completed and it was issued a Form 483 with 8 observations. The company will address them comprehensively within the stipulated timeline. The announcement was made after market hours yesterday, 20 August 2019.

Sun Pharma Advanced Research Company (SPARC) dropped 2.01%. The company said that a complaint has been filed by Abraxis Biosciences LLC in the U.S. District Court for the District of New Jersey, which alleges that SPARC's filing of New Drug Application (NDA) for Taclantis injection (Paclitaxel Injection Concentrate for Suspension) is an act of infringement of the Orange Book listed patents for Abraxane. The announcement was made after market hours yesterday, 20 August 2019.

Alembic Pharmaceuticals rose 3.03% after the company's Bioequivalence Facility located at Vadodara was inspected by US Food & Drug Administration (USFDA) between 12 August 2019 to 16 August 2019 and between 12 August 2019 to 20 August 2019 for Bioequivalence Bioanalytical and Bioequivalence Clinical. There were no 483s issued by USFDA at the end of the inspection. The announcement was made after market hours yesterday, 20 August 2019.

SpiceJet rose 1.63%. SpiceJet will shift its entire Mumbai operations to Terminal 2 of the city's Chhatrapati Shivaji Maharaj International Airport with effect from 1 October 2019. The transition is being proactively planned and implemented by the airline with the active support of Mumbai International Airport Limited (MIAL) to enhance passenger convenience. . It will lead to better synergies and cut down costs substantially for the airline. The announcement was made after market hours yesterday, 20 August 2019.

Zensar Technologies slipped 0.04%. Zensar Technologies announced that it has collaborated with Aptos, a recognized market leader in retail technology solutions, to support Aptos' development of next-gen cloud applications. With over 1,000 retail brands in 65 countries leveraging Aptos technology, the software vendor will utilise Zensar's expertise in digital solutions and services to accelerate and extend its research and development and professional services capabilities. The announcement was made after market hours yesterday, 20 August 2019.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 21 2019 | 9:26 AM IST

Next Story